标题
Targeting ERK beyond the boundaries of the kinase active site in melanoma
作者
关键词
-
出版物
MOLECULAR CARCINOGENESIS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-06-13
DOI
10.1002/mc.23047
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer
- (2018) Steven P. Angus et al. Annual Review of Pharmacology and Toxicology
- Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors
- (2018) Philippe Marchetti et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
- (2018) Shanshan Gu et al. BIOESSAYS
- ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
- (2018) Bijay S. Jaiswal et al. CLINICAL CANCER RESEARCH
- ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
- (2018) Andrew M. Kidger et al. PHARMACOLOGY & THERAPEUTICS
- Isoform-selective activity-based profiling of ERK signaling
- (2018) Myungsun Shin et al. Chemical Science
- MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
- (2018) Sobhana Babu Boga et al. ACS Medicinal Chemistry Letters
- ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers?
- (2018) Inna Smalley et al. Cancer Discovery
- Hyperactivation of MAPK Signaling is Deleterious to RAS/RAF Mutant Melanoma
- (2018) Grace P Leung et al. MOLECULAR CANCER RESEARCH
- Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
- (2018) Ida Aronchik et al. MOLECULAR CANCER RESEARCH
- Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
- (2018) Arun M Unni et al. eLife
- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
- (2017) Giulia Cesi et al. Molecular Cancer
- Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors
- (2017) Bernhard C. Lechtenberg et al. ACS Medicinal Chemistry Letters
- Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay
- (2016) Takayoshi Kinoshita et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The Nuclear Pore Complex as a Flexible and Dynamic Gate
- (2016) Kevin E. Knockenhauer et al. CELL
- Negative feedback regulation of the ERK1/2 MAPK pathway
- (2016) David Lake et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
- (2016) Nora Rauch et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- The ERK cascade inhibitors: Towards overcoming resistance
- (2016) Galia Maik-Rachline et al. DRUG RESISTANCE UPDATES
- Dissecting Therapeutic Resistance to ERK Inhibition
- (2016) S. Jha et al. MOLECULAR CANCER THERAPEUTICS
- Targeting mutant NRAS signaling pathways in melanoma
- (2016) Ha Linh Vu et al. PHARMACOLOGICAL RESEARCH
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)
- (2016) Andrew M. Kidger et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Conversion of graded phosphorylation into switch-like nuclear translocation via autoregulatory mechanisms in ERK signalling
- (2016) Yuki Shindo et al. Nature Communications
- Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants
- (2016) Lisa Brenan et al. Cell Reports
- Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
- (2015) Ana Herrero et al. CANCER CELL
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
- (2015) Eishu Hirata et al. CANCER CELL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- ERK1/2 can feedback-regulate cellular MEK1/2 levels
- (2015) Seung-Keun Hong et al. CELLULAR SIGNALLING
- Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma
- (2015) Daniel Verduzco et al. EXPERIMENTAL DERMATOLOGY
- Receptor Level Mechanisms Are Required for Epidermal Growth Factor (EGF)-stimulated Extracellular Signal-regulated Kinase (ERK) Activity Pulses
- (2015) Breanne Sparta et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting cancer with kinase inhibitors
- (2015) Stefan Gross et al. JOURNAL OF CLINICAL INVESTIGATION
- Systematic discovery of linear binding motifs targeting an ancient protein interaction surface on MAP kinases
- (2015) A. Zeke et al. Molecular Systems Biology
- Frequency modulation of ERK activation dynamics rewires cell fate
- (2015) H. Ryu et al. Molecular Systems Biology
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural assembly of the signaling competent ERK2–RSK1 heterodimeric protein kinase complex
- (2015) Anita Alexa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- Signal Transduction in Cancer
- (2015) R. Sever et al. Cold Spring Harbor Perspectives in Medicine
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
- (2014) E. M. Goetz et al. CANCER RESEARCH
- ERKs in Cancer: Friends or Foes?
- (2014) Xavier Deschênes-Simard et al. CANCER RESEARCH
- Targeted protein degradation as a tumor suppressor
- (2014) Nezahat Ozlem Arat et al. CELL CYCLE
- ERK Oscillation-Dependent Gene Expression Patterns and Deregulation by Stress Response
- (2014) Katrina M. Waters et al. CHEMICAL RESEARCH IN TOXICOLOGY
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer
- (2014) G. L. Johnson et al. CLINICAL CANCER RESEARCH
- An allosteric add-on
- (2014) Zachariah H Foda et al. Nature Chemical Biology
- A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
- (2014) Apirat Chaikuad et al. Nature Chemical Biology
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
- (2014) Anna A. Marusiak et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Protein–peptide complex crystallization: a case study on the ERK2 mitogen-activated protein kinase
- (2013) Gergő Gógl et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence
- (2013) Jimin Shin et al. CELLULAR SIGNALLING
- Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation
- (2013) X. Deschenes-Simard et al. GENES & DEVELOPMENT
- Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma
- (2013) Ao-Xue Wang et al. IUBMB LIFE
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- The epigenetics of epithelial-mesenchymal plasticity in cancer
- (2013) Wai Leong Tam et al. NATURE MEDICINE
- Molecular basis of MAP kinase regulation
- (2013) Wolfgang Peti et al. PROTEIN SCIENCE
- Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
- (2013) M. J. Niederst et al. Science Signaling
- ERK Pathway Inhibitors: How Low Should We Go?
- (2013) M. H. Nissan et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Docking Interactions of Hematopoietic Tyrosine Phosphatase with MAP Kinases ERK2 and p38α
- (2012) Andrea Piserchio et al. BIOCHEMISTRY
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Targeting the Regulatory Machinery of BIM for Cancer Therapy
- (2012) Hisashi Harada et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
- (2012) J. S. Logue et al. GENES & DEVELOPMENT
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals
- (2012) John G. Albeck et al. MOLECULAR CELL
- Monomeric and dimeric models of ERK2 in conjunction with studies on cellular localization, nuclear translocation, and in vitro analysis
- (2012) Sunbae Lee et al. MOLECULES AND CELLS
- Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
- (2012) A S Little et al. ONCOGENE
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Specificity of Linear Motifs That Bind to a Common Mitogen-Activated Protein Kinase Docking Groove
- (2012) A. Garai et al. Science Signaling
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
- (2012) Sarat Chandarlapaty Cancer Discovery
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- Activated ERK2 Is a Monomer in Vitro with or without Divalent Cations and When Complexed to the Cytoplasmic Scaffold PEA-15
- (2011) Tamer S. Kaoud et al. BIOCHEMISTRY
- Solution NMR Insights into Docking Interactions Involving Inactive ERK2
- (2011) Andrea Piserchio et al. BIOCHEMISTRY
- Substrate-Dependent Control of ERK Phosphorylation Can Lead to Oscillations
- (2011) Ping Liu et al. BIOPHYSICAL JOURNAL
- Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
- (2011) Sarice R Boston et al. BMC CANCER
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Global quantification of mammalian gene expression control
- (2011) Björn Schwanhäusser et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Model of a MAPK•Substrate Complex in an Active Conformation: A Computational and Experimental Approach
- (2011) Sunbae Lee et al. PLoS One
- The Effect of Arrestin Conformation on the Recruitment of c-Raf1, MEK1, and ERK1/2 Activation
- (2011) Sergio Coffa et al. PLoS One
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
- (2010) Yohannes Mebratu et al. CELL CYCLE
- Quantitative Analysis of ERK2 Interactions with Substrate Proteins
- (2010) Kimberly A. Burkhard et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Structure–activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1/2 inhibitors
- (2009) Qianbin Li et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
- (2009) Sebastien Cagnol et al. FEBS Journal
- Rapid and sustained nuclear–cytoplasmic ERK oscillations induced by epidermal growth factor
- (2009) Harish Shankaran et al. Molecular Systems Biology
- A new screening assay for allosteric inhibitors of cSrc
- (2009) Jeffrey R Simard et al. Nature Chemical Biology
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
- (2008) S. Giordano et al. CURRENT MEDICINAL CHEMISTRY
- Essential Role of ERK Dimers in the Activation of Cytoplasmic but Not Nuclear Substrates by ERK-Scaffold Complexes
- (2008) Berta Casar et al. MOLECULAR CELL
- Killing two kinase families with one stone
- (2008) Benoit Bilanges et al. Nature Chemical Biology
- Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
- (2008) J. L. Stebbins et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unique MAP Kinase binding sites
- (2007) Radha Akella et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started